Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Long-Term Investments (2016 - 2025)

UroGen Pharma's Long-Term Investments history spans 10 years, with the latest figure at $380000.0 for Q3 2025.

  • For Q3 2025, Long-Term Investments rose 117.14% year-over-year to $380000.0; the TTM value through Sep 2025 reached $380000.0, up 117.14%, while the annual FY2024 figure was $5.0 million, 11.55% up from the prior year.
  • Long-Term Investments reached $380000.0 in Q3 2025 per URGN's latest filing, up from $177000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $8.3 million in Q2 2021 to a low of $175000.0 in Q2 2024.
  • Average Long-Term Investments over 5 years is $1.4 million, with a median of $224000.0 recorded in 2023.
  • The largest YoY upside for Long-Term Investments was 3617.49% in 2021 against a maximum downside of 96.22% in 2021.
  • A 5-year view of Long-Term Investments shows it stood at $223000.0 in 2021, then changed by 0.0% to $223000.0 in 2022, then soared by 1918.83% to $4.5 million in 2023, then increased by 11.55% to $5.0 million in 2024, then plummeted by 92.43% to $380000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Long-Term Investments are $380000.0 (Q3 2025), $177000.0 (Q2 2025), and $4.5 million (Q1 2025).